Difference between revisions of "Lestaurtinib (CEP-701)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| − | + | ==Mechanism of action== | |
| + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lestaurtinib NCI Drug Dictionary]: An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. | ||
==Also known as== | ==Also known as== | ||
Revision as of 10:35, 4 July 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3.
Also known as
- Code name: CEP-701